| Literature DB >> 27272046 |
S Mas1,2,3, P Gassó1,2,3, A Lafuente1,2,3, M Bioque2,3,4, A Lobo3,5, A Gonzàlez-Pinto3,6, M S Olmeda7, I Corripio3,8, A Llerena9, B Cabrera2,3,4, J Saiz-Ruiz3,10, M Bernardo2,3,4,11.
Abstract
This study investigated whether the risk of presenting antipsychotic (AP)-induced extrapyramidal symptoms (EPS) could be related to single-nucleotide polymorphisms (SNPs) in a naturalistic cohort of first episode psychosis (FEP) patients. Two hundred and two SNPs in 31 candidate genes (involved in dopamine, serotonin and glutamate pathways) were analyzed in the present study. One hundred and thirteen FEP patients (43 presenting EPS and 70 non-presenting EPS) treated with high-potency AP (amisulpride, paliperidone, risperidone and ziprasidone) were included in the analysis. The statistical analysis was adjusted by age, gender, AP dosage, AP combinations and concomitant treatments as covariates. Four SNPs in different genes (DRD2, SLC18A2, HTR2A and GRIK3) contributed significantly to the risk of EPS after correction for multiple testing (P<1 × 10(-4)). These findings support the involvement of dopamine, serotonin and glutamate pathways in AP-induced EPS.Entities:
Mesh：
Substances：
Year: 2016 PMID： 27272046 DOI： 10.1038/tpj.2016.44
Source DB: PubMed Journal: Pharmacogenomics J ISSN： 1470-269X Impact factor: 3.550